Forthcoming webinars - information and registration.

Speaker: Giuseppe Lippi
Moderator: Dirk Roggenbuck
Date: 22nd January at 18:00 CET

Registration is open (enter the course to register).
How to enter the course?

Abstract: Sepsis is a severe, often life-threatening, condition developing when the organism’s response to an infection triggers a paramount biological effect, which finally generate injuries to its own tissues and organs, up to septic shock, multi-organ failure (MOF) and death. Evidence has been provided that the measurement of some biomarkers in serum or plasma may have clinical values for diagnosing and monitoring sepsis. Consensus has now been reached that procalcitonin is the biomarker for which the most solid evidence has been garnered, that whatever sepsis biomarkers shall always be available on prescription, that test results should always be interpreted according to clinical data, and that test ordering should follow specific biomarker’s kinetics. Sepsis biomarkers assessment may be sometimes combined for diagnosing sepsis. In such case, the combination of procalcitonin with C reactive protein (CRP) or presepsin is the most widely suggested. Sepsis biomarkers should be integrated into diagnostic threshold, prioritizing the high negative predictive value and based on analytically sensitive techniques. Evidence is also strongly emerging that some of these biomarkers, especially procalcitonin and presepsin, may retain clinical usefulness for antibiotic stewardship, and that serial testing shall be set according to biomarker’s kinetics. The assessment of biomarkers other than procalcitonin, presepsin and CRP is now discouraged, at least until stronger evidence will be published. Molecular biology techniques are also emerging as potential alternatives for rapid etiological diagnosis of infections. Further refinements of molecular assays would probably help overcoming the current limitations of their diagnostic performance.

Speaker: Hans Hoffmann (DE)
Moderator: Giuseppe Lippi (IT)

Date: 12th Fbruary 2019 at 18:00 CET


To be added

Speaker: Abdurrahman Coşkun
Moderator: Merve Sibel Gungoren

Date: 14th May at 18:00 CET

Registration is open (enter the course to register).

How to enter the course?

Internal quality control (QC) is the backbone of quality system in laboratory medicine, which serves to validate patients test results. However, it monitors the system intermittently, not continuously. Classical QC monitoring system depends on periods such as weeks, days, or predetermined time intervals and therefore detects some but not all analytical defects. In this situation, we have not much information about what is going on between these periods. To overcome this problem, we need a real-time monitoring system to detect the possible errors while the instruments are running.

Autoverification programs evaluate and release test results as soon as they receive data from the instruments. Therefore, when we detect errors using classical QC monitoring system, the test results of a large number of patients might have been reported to clinicians and/or patients already. This is a major risk for patients’ safety and when we detect errors, it wouldn’t be easy to re-analyse all reported patients’ samples. 

The devil is in the detail. We should monitor the system continuously using a suitable algorithm based on patients’ data. The aim of this webinar is to raise awareness for the necessity to monitor analytical instruments continuously while reporting test results.